Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mifepristone is a potent antagonist of steroid hormone receptors such as glucocorticoid and progesterone receptors. We investigated the potential for mifepristone to act as an antiandrogen and compared it with partial androgen receptor (AR) agonists and antagonists, in particular bicalutamide. Mifepristone was an effective antiandrogen in vitro that inhibited transcription from three androgen-responsive promoters and blocked the agonist R1881 in a dose-dependent manner. Like bicalutamide, mifepristone also antagonized the action of androgen receptor with a (T877A) mutation. Mifepristone competed effectively with R1881 with a relative binding affinity comparable to that of cyproterone acetate, and much higher than that of hydroxyflutamide and bicalutamide in a binding assay. Mifepristone could effectively induce the binding of the herpes simplex viral protein 16/AR fusion protein to the hormone response elements in the murine mammary tumor virus-luciferase reporter. With either wild-type or T877A mutant AR, mifepristone alone was unable to induce any detectable interaction with coactivators transcriptional intermediary factor-2 or beta-catenin but could inhibit the R1881-induced binding of AR to transcriptional intermediary factor-2 and beta-catenin. Similarly, mifepristone could inhibit the R1881-induced N/C-terminal interaction in a dose-dependent manner even though mifepristone alone has no effect on the N/C-terminal interaction of AR. We found that mifepristone could induce a strong interaction between AR and corepressors nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors in both transactivation and two-hybrid assays to a greater degree than hydroxyflutamide, cyproterone acetate, and bicalutamide. The AR-corepressor interaction was also seen in coimmunoprecipitation assays. Finally, mifepristone at high concentrations induced a low level of prostate-specific antigen expression in LNCaP and antagonized prostate-specific antigen expression induced by R1881. Mifepristone also antagonized R1881 action on the growth of LNCaP prostate cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Zhang, J., Thomas, T. Z., Kasper, S., & Matusik, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.12.7837 · Cited by 219 · cited 1×
“PSA/PSE-Luc was a gift from Arie Belldegrun, UCLA Medical Center (42) and probasin-Luc from Robert Matusik, Vanderbilt University (Nashville, TN) ( 58 ).”
Song, L.-N., Herrell, R., Byers, S., Shah, S., Wilson, E. M., & Gelmann, E. P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1674-1687.2003 · Cited by 169
Self-citationInhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., & Balk, S. P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0870 · Cited by 121
Cited by
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Isikbay, M., Otto, K., Kregel, S., Kach, J., Cai, Y., Vander Griend, D. J., Conzen, S. D., & Szmulewitz, R. Z. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0173-2 · Cited by 274
Herbst, A., Jurinovic, V., Krebs, S., Thieme, S. E., Blum, H., Göke, B., & Kolligs, F. T. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-74 · Cited by 212
“Whereas the steroid hormone biosynthesis pathway [101,102] as well as the endocytosis pathway [103,104], the insulin signaling pathway [105,106], apoptosis [107,108], regulation of the actin cytoskeleton [49], and focal adhesion [109], have been associated with Wnt/β-catenin signaling, there are no publications in the…”
Background
Metadata
- Authors
- Song, L.-N., Coghlan, M., & Gelmann, E. P.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2004-01
- Volume
- 18
- Issue
- 1
- Pages
- 70-85
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2146104410
- Cited by
- 116
- References
- 5
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.